On May 28, 2026 TG Therapeutics, Inc. (NASDAQ: TGTX) reported that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 2-4, 2026. The fireside chat is scheduled to take place on Wednesday, June 3, 2026, at 11:40 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at View Source

(Press release, TG Therapeutics, MAY 28, 2026, View Source [SID1234666155])

On May 28, 2026 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, reported that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

(Press release, Aclaris Therapeutics, MAY 28, 2026, View Source [SID1234666154])

On May 28, 2026 Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, reported that its Phase 1 OCTOPOD-IP clinical trial of THEO-260, a novel oncolytic immunotherapy, given by intraperitoneal delivery in patients with Platinum-Resistant Ovarian Cancer will be presented as a ‘Trials in Progress’ poster at the 2026 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) World Congress. ASCO (Free ASCO Whitepaper) is taking place in Chicago, US from May 29 – June 2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial is led by Amir A. Jazeri, MD, Vice Chair for Clinical Research and the Director of the Gynecologic Cancer Immunotherapy Program in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center.

Details of the ASCO (Free ASCO Whitepaper) presentation are:

A phase I trial of intraperitoneal THEO-260 in patients with high-grade serous or endometrioid ovarian cancer

· Presenter: Amir A. Jazaeri, MD,

· Abstract Number: TPS5635

· Session: Gynecologic Cancer

· Poster Board: 297b

· Place / Time: Hall A, Monday June 1, 09.00-12.00am (CDT)

The abstract is available online on the ASCO (Free ASCO Whitepaper) website (click here).

Dr. Jazaeri commented, "Ovarian cancer remains a significant cause of death in the US with almost 18,000 women predicted to die from the disease in 2026. Within this patient population, platinum-resistant ovarian cancer presents a high unmet need with few effective treatment options, and I am excited to lead this clinical trial to investigate whether THEO-260 can bring significant benefit to these patients."

David Apelian, Theolytics’ CEO, added, "Ovarian and other solid cancers are characterized by a rich stromal component with a high proportion of cancer-associated fibroblasts (CAFs). This creates an immunosuppressive environment that limits the therapeutic impact of immunotherapy approaches. With THEO-260, we aim to overcome this barrier by harnessing its ability to target and destroy cancer cells and CAFs and explore complementary routes of administration through IP delivery in the US OCTOPOD-IP trial and IV delivery in our ongoing Phase 1/2a OCTOPOD-IV trial in the UK, Spain and Canada."

The US OCTOPOD-IP trial (NCT07211659) will assess the safety and tolerability of THEO-260 administered directly to the peritoneal cavity (IP delivery) in PROC patients and includes extensive biomarker studies to showcase THEO-260’s differentiated mode of action.

(Press release, Theolytics, MAY 28, 2026, View Source [SID1234666153])

On May 28, 2026 Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, reported that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference Details
Format: Fireside Chat
Date: Thursday, June 4, 2026
Time: 12:50 PM ET
Webcast: Click Here

Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.

The webcast can also be accessed on the Events page of the Investors section of the Relmada website at View Source An archived replay will be available for 90 days following the conclusion of the event.

(Press release, Relmada Therapeutics, MAY 28, 2026, View Source [SID1234666152])

On May 28, 2026 Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, reported that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8,539,709 shares of its common stock at a purchase price of $0.5855 per share in a registered direct offering priced at-the-market under Nasdaq rules to GMS Ventures and Investments, the Company’s largest stockholder. The closing of the offering is expected to occur on or about May 29, 2026, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the Company from the offering are expected to be $5.0 million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from this offering, together with existing cash and cash equivalents, for working capital and general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the "SEC") on March 28, 2024, and that became effective on April 5, 2024. The offering of the securities in the registered direct offering is being made only by means of a base prospectus and prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus, when available, may also be obtained, when available, from the Company at 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830, by phone at (609) 619-3990 or e-mail at [email protected].

The Company also has agreed to amend certain outstanding common stock warrants to purchase up to an aggregate of 15,488,570 shares of common stock previously issued to GMS Ventures and Investments in January 2025 and May 2025, with a weighted average exercise price of $1.78 per share, effective upon the closing of the offering, such that the amended warrants will have a reduced exercise price of $0.5855 per share.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Outlook Therapeutics, MAY 28, 2026, View Source [SID1234666151])